Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Stopped early · Not applicable · Has a placebo group

Conditions studied: Overactive Bladder

In brief

We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis * Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) * Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin

Key facts

Study ID

NCT02070042

Run by

TriHealth Inc.

People needed

31

Starts

2014-02-01

Expected to finish

2015-09-01

Last updated by the study team

2018-01-31

Who can join

Age: 18 and older, up to 85. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women between the ages of 18-85; Desiring treatment for symptoms of urinary frequency, defined as >8 voids/day and/or nocturia > 1 void/night or urge incontinence episodes of >1/day

You may not qualify if…

• Bleeding disorder; Uncontrolled diabetes; Hypotension; Liver disease, such as hepatitis A/B/C, cirrhosis, acute fatty liver, liver tumors; Post voiding residual (PVR) > 150 on more than one occasion; Uncontrolled narrow-angle glaucoma; Hematuria of unknown cause; Obstructive uropathy; Known hypersensitivity to study medications; Recent use of study/omega 3 or anticholinergic medication in the prior 3 weeks with an inability to discontinue this medication; Planning any surgery in the 6 weeks of study duration

Where it is running

• Good Samaritan Hospital — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.